BIAF bioAffinity Technologies, Inc.
USHealthcareAs of 2026-07-10 16:00
Why BIAF matters now
bioAffinity Technologies, Inc. (BIAF) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.77 with -1.49% on the session and $3.5M in market capitalization; recent performance reads 1-month -50.75% and YTD -29.05%.
The latest financial table shown here is Q1 2026, with revenue of $1.4M, net income of $-3.6M, and EPS of $-0.81. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -286.3%.
The latest indexable market news headline is "BIAF Stock Plunges 77% in 3 Months: Should You Still Hold or Sell?" from Zacks Investment Research.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.03
P/S
0.67
EV/EBITDA
-0.14
DCF Value
$-300.59
FCF Yield
-286.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
22.1%
Operating Margin
-204.3%
Net Margin
-280.6%
ROE
-358.8%
ROA
-199.9%
ROIC
-229.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.4M | $-3.6M | $-0.81 |
| Q4 2025 | $1.6M | $-3.1M | $-1.82 |
| FY 2025 | $6.2M | $-14.9M | $-8.66 |
| Q3 2025 | $1.4M | $-5.1M | $-4.74 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Country
US
Exchange
—
Beta
-1.33
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.